Xeroderma Pigmentosum
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
2100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Clinuvel PharmaceuticalsAustralia - Melbourne
2 programs2
AfamelanotidePhase 2Peptide1 trial
AfamelanotidePhase 2Peptide1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Clinuvel PharmaceuticalsAfamelanotide
Clinuvel PharmaceuticalsAfamelanotide
Clinical Trials (2)
Total enrollment: 12 patients across 2 trials
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Start: Mar 2022Est. completion: Dec 20246 patients
Phase 2Unknown
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
Start: Oct 2021Est. completion: Oct 20246 patients
Phase 2Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.